Excess radiation absorbed doses from non-optimised radioiodine treatment of hyperthyroidism

Radiation Protection Dosimetry

Volumn 108, Issue 2, 2004, Pages 107-114

  Jönsson, Helene ^a,b   Mattsson, Sören ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Swedish Radiation Protection Authority   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RADIOACTIVE IODINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DOSIMETRY; DRUG EFFICACY; DRUG SAFETY; FAMILY; FEMALE; GRAVES DISEASE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PUBLIC HEALTH; RADIATION ABSORPTION; RADIATION EXPOSURE; RADIATION PROTECTION; SWEDEN; THYROID GLAND; UNIVERSITY HOSPITAL;

ABSORPTION; FEMALE; GRAVES DISEASE; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; MALE; RADIATION DOSAGE; RADIATION PROTECTION; RADIOMETRY; TIME FACTORS;

EID: 1542286684     PISSN: 01448420     EISSN: None     Source Type: Journal    
DOI: 10.1093/rpd/nch013     Document Type: Article

References (43)

1. Shapiro, B. Optimization of radioiodine therapy of thyrotoxicosis: What have we learned after 50 years? J. Nucl. Med. 34, 1638-1641 (1993).
2. Hays, M. Hypothyroidism following iodine-131 therapy. J. Nucl. Med. 23, 176-179 (1982).
3. Zanzonico, P. Internal radionuclide radiation dosimetry: A review of basic concepts and recent developments. J. Nucl. Med. 41, 297-308 (2000).
4. Wartofsky, L., Glinoer, D., Solomon, B. and Lagasse, R. Differences and similarities in the treatment of diffuse goiter in Europe and the United States. Exp. Clin. End. 97, 243-251 (1991).
5. International Commission on Radiological Protection. 1990 Recommendations of the International Commission on radiological protection. ICRP Publication 60. Ann. ICRP 21(1-3), (1991).
6. International Commission on Radiological Protection. Recommendations of the International Commission on radiological protection. ICRP Publication 26. Ann. ICRP 1(3), (1977).
7. European Communities. Council directive 97/43/Euratom of 30 June 1997 on health protection of individuals against the dangers of ionising radiation in relation to medical exposure. Official Journal of the European Communities L180, 9 July 1997.
8. The Swedish Radiation Protection Authority. The Swedish Radiation Protection Institute's Regulations and General Advice on Nuclear Medicine. SSI FS 2000:3. (2000).
9. Nordyke, R., Gilbert, F. and Gilbert Jr, F. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease J. Nucl. Med. 32, 411-416 (1991).
10. Ratcliffe, G., Fogelman, I. and Maisey, M. The evaluation of radioiodine therapy for thyroid patients using a fixed-dose regime. Br. J. Rad. 59, 1105-1107 (1986).
11. Jarlov, A., Hegedus, L., Kristensen, L., Nygaard, B. and Hansen, J. Is calculation of the dose in raioiodine therapy of hyperthyroidism worth while? Clin. End. 45, 325-329 (1995).
12. de Bruin, T., Croon, C., de Klerk, J. and van Isselt, J. Standardized radioiodine therapy in Graves' disease: the persistent effect of thyroid weight and radioiodine uptake on outcome. J. Intern. Med. 236, 507-513 (1994).
13. Clerc, J., Izembart, M., Dagousset, F., Heshmati, J., Chevalier, A., Léger, A. and Barritault, L. Influence of dose selection on absorbed dose in radioiodine treatment of diffuse toxic goiters inpatients receiving or not receiving carbimazole. J. Nucl. Med. 34, 387-393 (1993).
14. Traino, A., Di Martino, F., Lazzeri, M. and Stabin, M. Influence of thyroid volume reduction on calculated dose in radioiodine therapy of Graves' hyperthyroidism. Phys. Med. Biol. 45, 121-129 (2000).
15. Di Martino, F., Traino, A., Brill, A., Stabin, M. and Lazzeri, M. A theoretical model for prescription of the patient specific therapeutic activity for radioiodine therapy of Graves' disease. Phys. Med. Biol. 47, 1493-1499 (2002).
16. Jönsson, H. and Mattsson, S. Single uptake measurement for absorbed dose planning for radioiodine treatment of hyperthyroidism. Cancer Biother. Radiopharm. 18, 473-479 (2003).
17. Kok, S., Smit, J., De Craen, A., Goslings, B., Van Eck-Smit, B. and Romjin, J. Clinical outcome after standardized versus dosimetric radioiodine treatment of hyperthyroidism: an equivalence study. Nucl. Med. Com. 21, 1071-1078 (2000).
18. Bajnok, L., Mezosi, E., Nagy, E., Szabo, J., Sztojka, I., Varga, J., Galuska, L. and Leovey, A. Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary? Thyroid 9, 865-869 (1999).
19. Berg, G., Michanek, A., Holmberg, E. and Fink, M. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements. J. Nucl. Med. 37, 228-232 (1996).
20. 131Iodine activity. Results from a prospective, randomised, multicentre study. Eur. J. Clin. Invest. 25, 883-884 (1995).
21. Willemsen, U. F., Knesewitsch, P., Kreisig, T., Pickardt, C. R. and Kirsch, C. M. Functional results of radioiodine therapy with a 300 Gy absorbed dose in Graves' disease. Eur. J. Nucl. Med. 20, 1051-1055 (1993).
22. Rajashekharrao, B. Thyroidal absorbed dose from a standard five-millicurie iodine-131 (185 MBq) dose for thyrotoxicosis: Cure can occur with less than the conventional 7000 rads. J. Nucl. Med. 32, 364-365 (1991).
23. Haase, A., Bahre, M., Lauer, I., Meller, B. and Richter, E. Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose. Exp. Clin. Endocrinol. Diabetes. 108, 133-137 (2000).
24. Marinelli, L. D., Quimby, E. H. and Hine, G. J. Dosage determination with radioactive isotopes, practical considerations in therapy and protection. Amer. J. Roentgenol. 2, 260-281 (1948).
25. Jönsson, H., Mattsson, S., Bramstång, T. and Landberg, T. Absorbed dose to non-target organs at 131I-treatment of hyperthyroidism. In: Proceedings of Sixth International Radiopharmaceutical Dosimetry Symposium. Gatlinburg, Tennessee, May 1996. ORISE 99-0164, pp. 140-148 (1999).
26. Crespo, G. and Vetter, H. The calibration and standardization of thyroid radioiodine uptake measurements. Int. J. Appl. Radiat. Isotopes. 17, 531-549 (1966).
27. International Commission on Radiation Units and Measurements. Phantoms and computational models in therapy, diagnosis and protection. ICRU Report 48. J. ICRU (1992).
28. 131Iodine. J. Nucl. Med. 43, 856-861 (2002).
29. EANM (European Association of Nuclear Medicine). EANM procedure guidelines for therapy with iodine-131. Eur. J. Nucl. Med. 30, BP27-BP31 (2003).
30. Haenscheid, H., Laßmann, M. and Boerner, W. Aktivitaetsbestimmung vor Radiojodtherapie der Schilddruese-ein Vorschlag zur Minimierung von Aufwand und Fehler. Nuklearmedizin. 32, A 128 (1993).
31. Hall, P., Lundell, G. and Holm, L.-E. Mortality in patients treated for hyperthyroidism with iodine-131. Acta End. 128, 230-234 (1993).
32. Holm, L.-E. (15). Cancer risk after iodine-131 therapy for hyperthyroidism. J. Natl. Cancer Inst. 83, 1072-1077 (1991).
33. Ron, E. (14). Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 280(4), 347-355 (1998).
34. Alevizaki, C., Alevizaki-Harhalaki, M. and Ikkos, D. Radioiodine-131 treatment of thyrotoxicosis: dose required for and some factors affecting the early induction of hypothyroidism. Eur. J. Nucl. Med. 10, 450-454 (1985).
35. 131I. Wis. Med. J. 94, 21-25 (1995).
36. Lind, P. Strategies of radioiodine therapy for Graves' disease. Eur. J. Nucl. Med. 29(Suppl. 2), S453-S457 (2002).
37. Holm, L.-E. Changing annual incidence of hyperthyroidism after iodine-131 therapy for hyperthyroidism, 1951-1975. J. Nucl. Med. 23, 108-112 (1982).
38. Holm, L-E., Lundell, G., Israelsson, A. and Dahlqvist, I. Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism. J. Nucl. Med. 23, 103-107 (1982).
39. Catargi, B., Leprat, F., Guyot, M., Valli, N., Ducassou, D. and Tabarin, A. Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome. Eur. J. End. 141, 117-121 (1999).
40. Howarth, D., Epstein, M., Lan, L., Tan, P. and Booker, J. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study. Eur. J. Nucl. Med. 28, 1489-1495 (2001).
41. Bonnema, S., Bartalena, L., Toft, A. and Hegedüs, L. Controversies in radioiodine therapy: relation to ophtalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres. Eur. J. End. 147, 1-11 (2002).
42. Moka, D., Dietlein, H. and Schicha, H. Radioiodine therapy and thyrostatic drugs and iodine. Eur. J. Nucl. Med. 29(Suppl. 2), S486-S491 (2002).
43. Reinhardt, M., Brink, I., Joe, A., von Mallek, D., Ezziddin, S., Palmedo, H. and Krause,T. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur. J. Nucl. Med. 29, 1118-1124 (2002).